Vinodh Narayanan
Neurology with Special Qualifications in Child Neurology · Phoenix, AZNPI 1801900584
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,500 of the $5,083 with a category attached, or 68.9%. Acadia Pharmaceuticals Inc accounts for 69.9% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $3,378, more than ten times the $191 reported in 2019.
Across 84 payments — averaging $60.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$4K
- Impulse Dynamics (USA) Inc.$281
- UCB, Inc.$261
- Eisai Inc.$116
- Zogenix Inc.$110
- SK Life Science, Inc.$108
- plus $656 from 14 others
Across 67 payments — averaging $5480.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$361K
- Novartis$6K
What the payments were for
- Consulting fees$2816%
- Speaking & faculty fees$3,50069%
- Food & beverage$1,27025%
- Education$321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 7 | $3,551 |
| Impulse Dynamics (USA) Inc. | 1 | $281 |
| UCB, Inc. | 13 | $261 |
| Eisai Inc. | 7 | $116 |
| Zogenix Inc. | 5 | $110 |
| SK Life Science, Inc. | 2 | $108 |
| Greenwich Biosciences, Inc. | 6 | $106 |
| Jazz Pharmaceuticals Inc. | 3 | $95 |
| Aquestive Therapeutics, Inc. | 4 | $72 |
| Sunovion Pharmaceuticals Inc. | 5 | $69 |
| Immedica Pharma US, Inc. | 1 | $49 |
| Neurelis, Inc. | 2 | $42 |
| AstraZeneca | 3 | $42 |
| Supernus Pharmaceuticals, Inc. | 3 | $37 |
| Astellas Pharma US Inc | 1 | $37 |
| Travere Therapeutics, Inc. | 17 | $32 |
| Springworks Therapeutics, Inc. | 1 | $30 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Novartis | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAYBUE$3,500
- OPTIMIZER SMART SYSTEM$281
How this compares
$5,083 in reported general payments places this provider in the 75th percentile of 49 neurology with special qualifications in child neurology providers in Arizona.
See all neurology with special qualifications in child neurology providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 32 | $607 |
| Amitriptyline Hcl | 11 | $132 |
| Baclofen | 11 | $116 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Phoenix
- Angus WilfongPhoenix$348K
- Clara ChowPhoenix$35K
- Saunder BernesPhoenix$27K
- Randa JarrarPhoenix$25K
- Jeffrey BuchhalterPhoenix$19K
- Korwyn WilliamsPhoenix$13K
- Harlori BainsPhoenix$12K
- Tamara ZachPhoenix$10K
- Javier CardenasPhoenix$6K
- Richard FryePhoenix$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.